Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 3

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 2(2)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT03187210Phase 1Suspended

Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

Role: collaborator

NCT03187223Phase 2Completed

Bendamustine and Melphalan in Myeloma

Role: collaborator

NCT01701076Phase 2Completed

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT01079117Phase 3Completed

Morphine Slow-release Capsules in Substitution Therapy

Role: lead

All 4 trials loaded